• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Mechanical thrombectomy for stroke patients anticoagulated with direct oral anticoagulants versus warfarin
BackgroundOutcomes after mechanical thrombectomy (MT) for large vessel occlusion (LVO) were compared between stroke patients anticoagulated with direct oral anticoagulants (DOACs) and those anticoagulated with warfarin.
Source: Journal of the Neurological Sciences - June 16, 2021 Category: Neurology Authors: Junpei Koge, Kanta Tanaka, Hiroshi Yamagami, Takeshi Yoshimoto, Kazutaka Uchida, Takeshi Morimoto, Kazunori Toyoda, Nobuyuki Sakai, Shinichi Yoshimura Source Type: research

Idarucizumab-facilitated intravenous thrombolysis in acute ischemic stroke: A therapeutic strategy requiring further investigation
Although dabigatran does a better job reducing the risk of cardioembolic stroke than warfarin in patients with non-valvular atrial fibrillation, 0.92 –1.34% of dabigatran users still develop isch emic stroke [1]. The usage of warfarin (even at a suboptimal therapeutic level) increases the risk of hemorrhagic transformation (HT) after intravenous thrombolysis (IT) [2]; therefore, current guidelines advise against performing IT in patients receiv ing any direct oral anti-coagulant (DOAC), including dabigatran [3].
Source: Journal of the Neurological Sciences - September 13, 2018 Category: Neurology Authors: Hsiao Yu-Jen, Tsai Yi-Te, Li-Kai Tsai, Fang Chen-wen Tags: Letter to the Editor Source Type: research

Intravenous thrombolysis in stroke patients taking novel oral anticoagulants: experience with the low-dose 0.6  mg/kg of recombinant tissue-type plasminogen activator. Case reports
In the last decade, the novel oral anticoagulant (NOAC) dabigatran (a direct thrombin inhibitor), rivaroxaban, apixaban and edoxaban (direct factor Xa inhibitors) have been approved for primary and secondary prevention of stroke in patients with atrial fibrillation (AF) [1]. Compared with vitamin k antagonists such as warfarin, the NOACs offer benefits in terms of efficacy, safety and convenience [2]. The only currently approved treatment for acute stroke with a class I recommendation and level A evidence is intravenous recombinant tissue-type plasminogen activator alteplase (IV rt-PA) [4].
Source: Journal of the Neurological Sciences - July 7, 2018 Category: Neurology Authors: Massimiliano Plastino, Domenico Bosco, Laura Giofr è, Dario Cristiano, Franco Galati, Paolo Postorino, Arturo Consoli, Antonietta Fava, Domenico Consoli Tags: Letter to the Editor Source Type: research

Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient
Novel oral anticoagulants (NOACs) are the recent therapeutic breakthrough in the thromboprophylaxis of non-valvular atrial fibrillation (NVAF). There are currently three different molecules approved for NVAF: dabigatran, rivaroxaban and apixaban. All three agents have demonstrated at least non-inferiority at major clinical endpoints compared to warfarin with their major advantage being the fixed-dose regimen that necessitates no regular blood tests and protects patients from the disastrous effects of infra-therapeutic (embolism) or supra-therapeutic (hemorrhage) anticoagulation.
Source: Journal of the Neurological Sciences - September 14, 2014 Category: Neurology Authors: Apostolos Safouris, Anne Demulder, Nikos Triantafyllou, Georgios Tsivgoulis Tags: Letter to the Editor Source Type: research

Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 — Implications for warfarin management and outcome in Croatian patients with acute stroke
Conclusion: Our data indicated rapid and safe anticoagulation achieved by using pharmacogenetically-predicted warfarin dose in high-risk acute stroke patients without increasing the risk of warfarin dosage complications in an elderly population.Highlights:
Source: Journal of the Neurological Sciences - May 6, 2014 Category: Neurology Authors: Svjetlana Šupe, Nada Božina, Vesna Matijević, Antonela Bazina, Antonija Mišmaš, Josip Ljevak, Domagoj Alvir, Mario Habek, Zdravka Poljaković Tags: Original Articles Source Type: research

Prevalence of genetic polymorphisms of and — Implications for warfarin management and outcome in Croatian patients with acute stroke
Source: Journal of the Neurological Sciences - May 4, 2014 Category: Neurology Authors: Svjetlana Šupe, Nada Božina, Vesna Matijević, Antonela Bazina, Antonija Mišmaš, Josip Ljevak, Domagoj Alvir, Mario Habek, Zdravka Poljaković Tags: Original Articles Source Type: research

Warfarin-associated intracerebral hemorrhage: Volume, anticoagulation intensity and location
Conclusions: Patients with warfarin-associated ICH have a predilection for brainstem ICH. After adjustment for ICH location, no relationship between admission INR and hematoma volume was found.
Source: Journal of the Neurological Sciences - August 1, 2013 Category: Neurology Authors: Minmin Ma, Atte Meretoja, Leonid Churilov, Gagan J. Sharma, Søren Christensen, Xinfeng Liu, Louise Weir, Stephen M. Davis, Bernard Yan Tags: Original Articles Source Type: research

Reservations against new oral anticoagulants after stroke and cerebral bleeding
Abstract: Dabigatran, rivaroxaban, and apixaban are the new oral anticoagulants (NOAC) which have been investigated in patients with atrial fibrillation (AF) for primary and secondary prevention of stroke and thromboembolism. In these trials NOAC had a similar efficacy and safety profile compared to traditional vitamin-K-antagonists such as warfarin. We advise caution in the use of NOAC in patients with stroke or cerebral hemorrhage because of the following reasons:1) Patients with cerebral bleeding were excluded from the trials. 2) Stroke within 14days and severe stroke within 6months before screening were exclusion crite...
Source: Journal of the Neurological Sciences - April 29, 2013 Category: Neurology Authors: Claudia Stöllberger, Josef Finsterer Tags: Opinion Source Type: research